We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App

Qiagen Launches CE-marked Version of QuantiFERON SARS-CoV-2 to Assess T-cell Response to COVID-19

By LabMedica International staff writers
Posted on 03 Dec 2021
Print article

QIAGEN N.V. (Venlo, Netherlands) has obtained the CE marking for its QuantiFERON SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.

COVID-19 vaccines stimulate the body to produce antibodies and activate T-cells to fight a SARS-CoV-2 infection. T-cell response to SARS-CoV-2 declines much more slowly than antibody response and may indicate how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those are who have recovered many months – possibly even years – after having been infected. Serology tests, which measure the antibodies, often generate positive test results after vaccination but are unable to assess cellular responses.

The QuantiFERON SARS-CoV-2 assay detects CD4+ and CD8+ T-cell responses, thereby enabling a much more comprehensive assessment of immunity generated by COVID-19 vaccines. The assay is based on QIAGEN’s QuantiFERON interferon gamma release technology, which is globally recognized as an easy-to-use T-cell assay that employs whole blood and – unlike other T-cell assays – does not require the purification of lymphocytes for T-cell measurement.

“T-cells provide valuable insights into our immune system’s response to COVID-19,” said Jean-Pascal Viola, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. “The more we know about this epidemic, the better equipped the world will be to address this threat that will stay with us,” he said. “We are excited about our QuantiFERON technology enabling the assessment of immune responses that are crucial for the prevention and management of the disease.”

Related Links:

Gold Supplier
Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit
Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Prepacked)
Electrolyte Analyzer
CARELYTE-500 Series
3-Part Diff Auto Hematology Analyzer
Cellagon 3
Coagulation Analyzer
DIAcheck C1

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more


view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.